Imagine a world where a $49 weight-loss pill could spark a legal battle worth millions. That’s exactly what’s happening right now, as pharmaceutical giant Novo Nordisk, the maker of Wegovy, has filed a federal lawsuit against telehealth company Hims & Hers. But here’s where it gets controversial: Novo Nordisk claims Hims & Hers is selling a knock-off version of its blockbuster weight-loss drug, Wegovy, at a fraction of the cost. This isn’t just about money—it’s about patient safety, innovation, and the integrity of the FDA’s approval process.
On February 9, 2026, Novo Nordisk took Hims & Hers to court in the U.S. District Court in Delaware, alleging patent infringement. This move came just days after Hims & Hers announced its plan to sell a compounded version of Wegovy for $49 per month. The timing is no coincidence. The Food and Drug Administration (FDA) had already threatened action against Hims & Hers, prompting the company to halt sales of its compounded pill on February 7. But the damage, according to Novo Nordisk, was already done.
At the heart of this dispute is semaglutide, the active ingredient in Wegovy. This drug, also sold under the brand name Ozempic for Type 2 diabetes, is the only glucagon-like peptide-1 (GLP-1) medication approved as a weight-loss pill. Novo Nordisk’s lawsuit argues that Hims & Hers is not just copying their product but bypassing the FDA’s rigorous review process, which ensures safety and efficacy. John Kuckelman, Novo’s senior vice president and group general counsel, called this practice “dangerous and deceptive to patients,” adding that it undermines the scientific innovation behind these treatments.
But here’s the part most people miss: The FDA has historically allowed compounding pharmacies to sell copies of drugs during shortages. In February 2025, the FDA declared the semaglutide shortage over and set deadlines to crack down on unauthorized copies. Yet, Hims & Hers allegedly continued to mass-produce injectable versions of Novo’s FDA-approved medications, raising serious concerns about patient health. Novo Nordisk claims this puts lives at risk, while Hims & Hers has yet to publicly respond to the lawsuit.
On February 6, the FDA announced plans to restrict GLP-1 ingredients used in compounded drugs marketed by Hims & Hers and other companies, citing quality, safety, and efficacy concerns. This move underscores the growing tension between innovation, accessibility, and regulation in the pharmaceutical industry.
Here’s the million-dollar question: Is Hims & Hers a disruptor making weight-loss treatments more affordable, or is it a dangerous player cutting corners at the expense of patient safety? And this is where you come in—what do you think? Is Novo Nordisk justified in its lawsuit, or is Hims & Hers filling a gap in the market? Let’s spark a conversation in the comments below!
